A systematic review and meta-analysis is needed to appraise the real efficacy and safety of MSC co-transplantation in allo-HSCT. A growing body of research on this subject exists, while the results of different trials are conflicting. However, its outcomes need further improvement, and co-infusion of mesenchymal stem cells (MSCs) may show promise. hematopoietic stem cell transplantation (allo-HSCT) is life-saving for severe hematological conditions. 6 Admin Office of Southwest Hospital, Army Medical University (Third Military Medical University), #30 Gaotanyan Street, Shapingba District, Chongqing, 400038, People's Republic of China. 5 Center for Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), #30 Gaotanyan Street, Shapingba District, Chongqing, 400038, People's Republic of China.1 Center for Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), #30 Gaotanyan Street, Shapingba District, Chongqing, 400038, People's Republic of China. 4 School of Nursing, Army Medical University (Third Military Medical University), Chongqing, People's Republic of China.3 Teaching-Research Office of Nursing, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, People's Republic of China.2 Admin Office of Southwest Hospital, Army Medical University (Third Military Medical University), #30 Gaotanyan Street, Shapingba District, Chongqing, 400038, People's Republic of China.1 Center for Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), #30 Gaotanyan Street, Shapingba District, Chongqing, 400038, People's Republic of China.In this review, we provide an overview of clinical trials using MSCs in allogeneic hematopoietic cell transplantation and discuss the possibilities and optimization of MSC therapy.Įngraftment Graft-versus-host disease Hematopoietic stem cell transplantation Mesenchymal stem cell. Besides, MSCs can also produce bone marrow stroma and promote hematopoiesis, the co-transplantation of hematopoietic stem cells and MSCs have been efficiently performed in cord blood transplantation and HLA-mismatched transplantation to enhance engraftment and prevent GVHD. Moreover, in Japan, allogeneic bone marrow-derived MSC product, TEMCELL ®, was approved as a regenerative medicine for acute GVHD. A number of clinical trials have demonstrated the safety and efficacy of MSC therapy for acute GVHD.
Because MSCs are capable of producing several cytokines and growth factors, they have been widely used in the treatment of graft-versus-host disease (GVHD). Mesenchymal stem cells (MSCs) have received considerable attention in allogeneic hematopoietic cell transplantation because of their abilities to modulate immune responses and promote hematopoiesis.
0 kommentar(er)
